2H7D image
Deposition Date 2006-06-02
Release Date 2007-01-30
Last Version Date 2024-11-20
Entry Detail
PDB ID:
2H7D
Title:
Solution structure of the talin F3 domain in complex with a chimeric beta3 integrin-PIP kinase peptide
Biological Source:
Source Organism:
Gallus gallus (Taxon ID: 9031)
(Taxon ID: )
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
100
Conformers Submitted:
20
Selection Criteria:
structures with the lowest energy
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Talin-1
Gene (Uniprot):TLN1
Mutations:C336S
Chain IDs:A
Chain Length:101
Number of Molecules:1
Biological Source:Gallus gallus
Polymer Type:polypeptide(L)
Molecule:Chimera of 24-mer peptide from Integrin beta-3 and 10-mer peptide from Phosphatidylinositol-4-phosphate 5-kinase type-1 gamma
Gene (Uniprot):Pip5k1c
Chain IDs:B
Chain Length:34
Number of Molecules:1
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR B TYR O-PHOSPHOTYROSINE
Ligand Molecules
Primary Citation
Structural basis of integrin activation by talin
CELL(CAMBRIDGE,MASS.) 128 171 182 (2007)
PMID: 17218263 DOI: 10.1016/j.cell.2006.10.048

Abstact

Regulation of integrin affinity (activation) is essential for metazoan development and for many pathological processes. Binding of the talin phosphotyrosine-binding (PTB) domain to integrin beta subunit cytoplasmic domains (tails) causes activation, whereas numerous other PTB-domain-containing proteins bind integrins without activating them. Here we define the structure of a complex between talin and the membrane-proximal integrin beta3 cytoplasmic domain and identify specific contacts between talin and the integrin tail required for activation. We used structure-based mutagenesis to engineer talin and beta3 variants that interact with comparable affinity to the wild-type proteins but inhibit integrin activation by competing with endogenous talin. These results reveal the structural basis of talin's unique ability to activate integrins, identify an interaction that could aid in the design of therapeutics to block integrin activation, and enable engineering of cells with defects in the activation of multiple classes of integrins.

Legend

Protein

Chemical

Disease

Primary Citation of related structures